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Despite its clinical significance, the mechanisms
of joint morphogenesis are elusive. By combining
laser-capture microdissection for RNA sampling
with microarrays, we show that the setting in which
joint-forming interzone cells develop is distinct from
adjacent growth plate chondrocytes and is charac-
terized by downregulation of chemokines, such
as monocyte-chemoattractant protein-5 (MCP-5).
Using in vivo, ex vivo, and in vitro approaches, we
show that low levels of interzone-MCP-5 are essential
for joint formation and contribute to proper growth
plate organization. Mice lacking the TGF-b-type-II-
receptor (TbRII) in their limbs (Tgfbr2Prx1KO), which
lack joint development and fail chondrocyte hyper-
trophy, show upregulation of interzone-MCP-5.
In vivo and ex vivo blockade of the sole MCP-5
receptor, CCR2, led to the rescue of joint formation
and growth plate maturation in Tgfbr2Prx1KO but an
acceleration of growth plate mineralization in control
mice. Our study characterized the TbRII/MCP-5 axis
as an essential crossroad for joint development and
endochondral growth.
INTRODUCTION
Synovial joints, which separate adjacent skeletal elements
from each other, are important signaling centers that control
chondrocyte maturation within the endochondral template
(Francis-West et al., 1999). Although their evolutionary, physio-
logical, and clinical significance, there is limited information on
the mechanisms and signaling molecules that lead to joint
morphogenesis. Morphologically, the position of each future
joint is first delimited by the interzone development, consisting
of a region of compactmesenchymal cells between two adjacent
growth plates. Interzone cells adopt a nonchondrogenic pheno-
type, as indicated by the loss of chondrogenic markers, such asDSox-9 and Collagen 2, and instead express new sets of genes,
including Gdf5, Wnt9a, and Wnt4 (Hartmann and Tabin, 2001;
Pacifici et al., 2006; Storm et al., 1994). There is limited infor-
mation of the entry mechanism leading to interzone initiation,
the gene expression environment in which interzone cells
emerge and make themselves distinct from adjacent growth
plate chondrocytes and how joint morphogenic molecules are
interconnected within the joint and with the other skeletogenic
components of the developing bone (Dowthwaite et al., 2004;
Koyama et al., 2008). Articular cartilage is avascular, and this
limits its reparative capacity such that arthritis is the single
largest cause of disability in the adult population (Centers for
Disease Control and Prevention, 2007). A greater understanding
of joint formation can provide critical insight on the pathogenesis
of joint degeneration and to develop novel reparative strategies
to treat arthritis.
In adult articular cartilage, inflammatory cytokines critically
target the joints causing their degeneration. Monocyte chemoat-
tractant protein-5 (MCP-5, also known as CCL12) belongs to the
family of CC chemokines and is the structural and functional
homolog of human MCP-1 (Sarafi et al., 1997). MCP-5 binds
exclusively to CC-chemokine receptor 2 (CCR2), which is the
primary receptor for human MCP-1 (Sarafi et al., 1997; Tsou
et al., 2007). MCP-5, as well as MCP-1, is a potent chemoattrac-
tant for circulating monocytes to sites of inflammation, where
they become cytokine-secreting macrophages (Charo and
Ransohoff, 2006; Mack et al., 2001; Sarafi et al., 1997). CCR-2
has received major clinical attention in arthritis, as it has been
regarded as a therapeutic target to be blocked (Charo and Ran-
sohoff, 2006; Quinones et al., 2005). An increased number of
CCR2+ cells are found in the inflamed joints of patients with
different forms of arthritis (Nanki et al., 2001; Ruth et al., 2001).
CCR-2 is also increased in rodent models of arthritis, although
levels change during the different phases of the disease (Szeka-
necz et al., 2000; Thornton et al., 1999). In addition, increased
levels of MCP-1 have been found in patients with osteoarthritis
(OA) and rheumatoid arthritis (RA) (De Benedetti et al., 1999;
Hayashida et al., 2001). These lines of evidence have led to the
development of several antagonists of and antibodies against
CCR-2 and MCP-1 (Feria and Diaz-Gonza´lez, 2006; Quinones
et al., 2005). Although the role of inflammatory cytokines, suchevelopmental Cell 23, 71–81, July 17, 2012 ª2012 Elsevier Inc. 71
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role in joint development has never been evaluated. A finding
of cytokine involvement in joint formation would determine a
shift in our current view of joint cells not anymore as passive
victims of the disruptive force of cytokines but as active partici-
pants in maintaining under control the cytokine effects and
therefore joint integrity.
Genetic manipulation of the TGF-b system has revealed
critical roles in both joint development and skeletogenesis
(Ito et al., 2003; Serra et al., 1997; Spagnoli et al., 2007). TGF-b
type II receptor (TbRII) is the only TbR that is capable of binding
all the TGF-b isoforms resulting in functional signaling. Mice that
are germline null for the Tgfbr2 exhibit early embryonic lethality,
making it impossible to evaluate the role of TGF-b signaling in
skeletogenesis (Oshima et al., 1996). In previous studies, by
generating the Tgfbr2-GFP-b-GEO-BAC imaging (b-Gal and
GFP) reporter mouse, we showed that TbRII is highly and
specifically expressed in developing joints (Spagnoli et al.,
2007). Furthermore, by generating a mouse in which the TbRII
signaling is conditionally inactivated in limb buds starting at
E9.5 (Tgfbr2Prx1KO), we demonstrated that the lack of TGF-b
signaling was associated with complete absence of interphalan-
geal joints as well as with impaired growth plate development
(Spagnoli et al., 2007).
In this study, we have found that the joint interzone emerges
within the developing limb mesenchyme expressing a gene-
expression pattern that is distinct from the adjacent developing
growth plate chondrocytes and is characterized by a down-
regulation of chemokines, in particular MCP-5. MCP-5 down-
regulation is impaired in the Tgfbr2Prx1KO mutants that lack joint
development. By using in vivo, ex vivo, and in vitro approaches
we demonstrated that an aberrant presence of MCP-5 within
the developing limb is sufficient to impair joint formation and
within the developing growth plate, to alter the rate of pro-
gression of prehypertrophic chondrocytes to hypertrophy and
mineralization. The in vivo and ex vivo blockade of the CCR2
signaling (MCP-5 sole receptor) in Tgfbr2Prx1KO mice led to a
rescue of their phenotype, restoring joint cavitation and expres-
sion of joint morphogenic genes while promoting the proper
growth plate maturation. To our knowledge, by demonstrating
the essential role of the TbRII/MCP-5 axis in the interplay
between the developing articular cartilage and the growth plate,
we provide evidence of a function for a cytokine during skeletal
development and open a novel prospective for evaluating and
therapeutically targeting the TbRII/MCP-5 axis in OA.
RESULTS
MCP-5 Is Differentially Expressed in Interzone Cells
and Adjacent Chondrocytes, and Such Expression
Pattern Is Impaired in Tgfbr2Prx1KO Mice
In order to investigate the distinct gene expression profile where
interzone cells emerge between the forming growth plates, we
obtained RNA samples from E14.5 interzone cells and adjacent
growth plate chondrocytes of Tgfr2flox/flox (normal control, NC)
and Tgfbr2Prx1KO digits using laser capturing microdissection
(LCM). Figure 1A depicts the regions that were subjected to
LCM; in the Tgfbr2Prx1KO, the presumptive interzone was identi-
fied as a bending between two growth plates. After verifying RNA72 Developmental Cell 23, 71–81, July 17, 2012 ª2012 Elsevier Inc.integrity (see Experimental Procedures), specimens were sub-
jected to microarray analysis. Normalized data were expressed
as fold changes of a candidate gene in the interzone sample
compared to the expression found in the sample from adjacent
growth plate chondrocytes. As initial validation step, we exam-
ined the expression of genes that we had previously found
to be specifically upregulated in the interzone compared to
adjacent growth plate chondrocytes by in situ hybridization
(ISH), immunohistochemistry (IHC), and real-time PCR (RT-PCR)
(Spagnoli et al., 2007). Microarray analysis confirmed that in
the NC interzone, Jagged1, Tgfbr2, Pdgfrb, and Wnt9a were
upregulated, respectively, 243.9-, 12.29-, 66.1-, and 3.43-fold,
compared to adjacent growth plate chondrocytes, whereas
such regulation was impaired in the Tgfbr2Prx1KO (respectively,
Jagged1, 1.32-fold; Tgfbr2, 1.27-fold; Pdgfrb, 0.97-fold;Wnt9a,
0.99-fold). Next, we performed a pathway analysis using the
PANTHER (protein analysis through evolutionary relationships)
Classification System (Celera) to identify functional categories
in the joint-forming interzone cells compared to adjacent growth
plate chondrocytes. The PANTHER is a unique resource that
classifies genes into canonical pathways to predict function
(Thomas et al., 2003). As shown in Figure 1B, we found that in
the NC interzone cells the ‘‘Inflammation mediated by chemo-
kine and cytokine signaling pathway’’ was extensively downre-
gulated compared to adjacent chondrocytes; of a total of 337
genes classified in this pathway, 227 were downregulated
more than 2-fold. Within the genes downregulated, Mcp-5
was downregulated 800-fold and its unique receptor, Ccr2,
11-fold, whereas such differential expression was impaired in
the Tgfbr2Prx1KO (Figure 1C). As further validation of the micro-
arrays data, we performed qRT-PCR on RNA samples obtained
by LCM from interzone and adjacent growth plate chondrocytes
from E14.5 NC and Tgfbr2Prx1KO as well as ISH and IHC analysis
on E14.5 limbs either from NC or Tgfbr2Prx1KO mice. As shown
in Figure 1D, qRT-PCR analyses showed that the expression of
Mcp-5 in NC interzone was more than 900-fold lower than its
expression in NC chondrocytes. In contrast, the Tgfbr2Prx1KO
presumptive interzone expressed levels of MCP-5 that were
higher than the NC interzone (more than 130-fold) and were
not significantly different from levels found in Tgfbr2Prx1KO
growth plate chondrocytes. ISH and IHC studies corroborated
these findings (Figures 1E and 1F).Our data show that the joint
interzone cells demonstrate a downregulation of MCP-5 mRNA
and protein levels compared to adjacent developing growth
plate cells and that such downregulation is abolished in
Tgfbr2Prx1KO developing limbs.
To determine MCP-5 expression through joint development
we extended IHC analyses of MCP-5 in E12.5; E13.5, E14.5;
E16.5 and E18.5 NC (Figure S1 available online). We found that
MCP-5 expression started at E13.5 within the developing digits.
By E14.5, MCP-5 expression was restricted to the growth plate
chondrocytes while was not expressed in the joint at any stage.
Aberrant Release of MCP-5 within Normal Developing
Limbs Alters Joint Formation, while Blockade of CCR2
Signaling Is Able to Rescue the Joint Phenotype
of Tgfbr2Prx1KO Mutants
In order to determine a role for the restricted levels of MCP-5
within the interzone, we used an ex vivo approach in which
Figure 1. MCP-5 Expression Is Downregulated in the Interzone of E14.5 NC Embryos Compared to Growth Plate Chondrocytes; This Expres-
sion Pattern Is Impaired in Tgfbr2Prx1KO
(A) Normal control (NC) and Tgfbr2Prx1KO sections before and after LCM of interzone cells (interz) and adjacent growth plate chondrocytes (chondr).
(B and C) Microarray and Panther analyses of the cDNAs from LCM showing the differential regulation of the ‘‘Inflammation mediated by chemokines and
cytokines’’ signaling pathway in NC interzone cells related to chondrocytes (B) and differential regulation ofMcp-5 and its receptorCcr2 in the interzone related to
chondrocytes of both NC and Tgfbr2Prx1KO (C).
(D) qRT-PCR analyses of LCM samples showing expression ofMcp-5 in the NC interzone, as well as the Tgfbr2Prx1KO presumptive interzone, compared to growth
plate chondrocytes; experiments were repeated three times, gel lanes represent two representative experiments; data are represented as mean ± SD, analyzed
using one-way ANOVA (p < 0.0001) followed by Bonferroni’s multiple comparison test (*p < 0.0001; **p < 0.05).
(E and F) Limb buds were dissected from E14.5 NC and Tgfbr2Prx1KO embryos, embedded in paraffin and subjected to (E) ISH and (F) IHC analyses using MCP-5
probe and anti-MCP-5 antibody (proximal side: right), respectively. Sections were obtained from at least four mutant and control embryos; at least six sections for
MCP-5 antibody and eight sections for MCP-5 probe were analyzed. MCP-5 expression pattern was consistent in all the specimens analyzed. The expression
pattern of MCP-5 at different joint developmental time points (E12.5, E13.5, E14.5, E16.5, and E18.5) is shown in Figure S1.
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loaded with MCP-5 protein were microinjected in the interzone
of E14.5 WT dissected autopods (Figure 2A) to lead to an aber-
rant sustained release of MCP-5 within the developing joints.DHGC nanoparticles are biocompatible and nonimmunogenic
and consist in hydrophilic shells and hydrophobic cores that
bind proteins (Hirano, 1999; Li et al., 2010). We have developed
a microinjection unit that allows for precise injection localizationevelopmental Cell 23, 71–81, July 17, 2012 ª2012 Elsevier Inc. 73
Figure 2. Aberrant Expression of Gdf5 and Collagen 2 in E14.5 WT
Embryos after HGC-MCP-5 Limb Implantation and Ex Vivo Culture
Recombinant MCP-5 was loaded in HGC-nanoparticle and the HGC-MCP-5
complex (MCP-5, 1.5 ng) was implanted in the 2nd, 3rd, and 4th digit (high-
lighted by Methylene blue) of dissected E14.5 WT. Injected and uninjected
(5th digit) limbs were cultured for 48 hr, embedded in paraffin, and subjected to
(A) IHC analyses using MCP-5 antibody and (B) ISH studies using Gdf5 and
Collagen 2 (Col2) probes (proximal side: right). Eight out of nine WT embryos
implanted with HGC-MCP-5 showed an altered phenotype, as described in
the Results; analyses were performed in at least three sections for each
embryo and for each probe.
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TbRII/MCP-5 Axis in Limb Developmentand volume accuracy delivery (nanoliters) within distinct regions
of developing autopods; by using this unit, we have previously
reported that proteins are slowly released from HGC without
diffusing (90% in 48 hr), are biologically active and HGC do
not interfere with skeletogenesis, including joint development
(Li et al., 2010). Based on these pharmacokinetics studies,
HGC-MCP-5 complex (delivering 1.5 ng of MCP-5 protein) was
injected at the joint sites of E14.5 dissected autopods that
were cultured for 2 days; uninjected joints from the same embryo
were used as control (Figure 2A). IHC for MCP-5 showed that
protein was sustainably delivered (after 48 hr) within the inter-
zone; Figure 2A shows that MCP-5 was detectable in the inter-
phalangeal joint sections from the 2nd digit implanted with
HCG-MCP-5, whereas it was undetectable in the uninjected
control joint interzone of the 5th digit, in which endogenous
MCP-5 was restricted to the adjacent growth plate chondro-
cytes. Compared to uninjected control, the aberrant sustained
delivery of MCP-5 from HCG-MCP-5 implant within the devel-74 Developmental Cell 23, 71–81, July 17, 2012 ª2012 Elsevier Inc.oping interzone abolished Gdf5 expression and altered the
interzone Collagen 2 expression pattern. In fact, the interzone
of implanted HCG-MCP-5 digits lost the characteristic chondro-
cyte segmentation and Collagen 2-expressing cells appeared
continuously distributed along the entire digit (Figure 2B).
Increasing doses (0.75 to 1.5 ng) of implanted MCP-5 within
the interzone resulted in gradual impairing of Gdf5 and Collagen
2 patterns. Similar effects on Gdf5 and Collagen 2 expressions
were found among the 1.5 to 6 ng doses; therefore, 1.5 ng was
used in all further experiments (data not shown). At least three
embryos were implanted with each dose, and at least three
sections from each embryo were subjected to ISH analyses.
To determine whether the blockade of CCR2 (the sole MCP5
receptor) would restore interphalangeal joint formation in
Tgfbr2Prx1KOdeveloping limbs,we used ex vivo, aswell as in vivo,
approaches. We first evaluated CCR2 expression by IHC at
different joint developmental time points (E12.5; E13.5, E14.5,
and E18.5). CCR-2 expression was first detected within the
developing digit at E13.5 and by E14.5 expression was found
within the developing interzone and growth plates. This expres-
sion pattern was maintained up to E18.5 (Figure S2). To block
the CCR2 signaling, we used the HCG-based ex vivo autopod
culture technique; in particular, we implanted HCG-MC-21 nano-
particles (delivering 1.5 ng ofMC-21 antibody) in the presumptive
interzoneof E14.5Tgfbr2Prx1KOmutants aswell asNC littermates.
The MC-21 is an anti-mouse CCR-2 monoclonal antibody that
has been shown to block the murine CCR-2 with high affinity
in vivo as well as in vitro (Bru¨hl et al., 2004; Mack et al., 2001).
Histological and ISH studies demonstrated that blockade of
MCP-5 signaling was able to restore the joint cavitation and
Gdf5 expression abnormally missing in the mutants. In addition,
whereas in mutant limbs Sox-9- andCollagen 2- expressing cells
were continuously distributed along the digit, in MC-21-im-
planted mutants they appeared to be restricted to the growth
plate chondrocytes, adopting an expression pattern that was
similar to controls (Figure 3A). For the in vivo studies, pregnant
females potentially carrying Tgfbr2Prx1KO embryos were treated
orallywith 4mg/Kg/dayofRS-504393 (a selectiveCCR2 inhibitor)
starting at E11.5 and until either E14.5 or E18.5, when mice were
sacrificed. The two time points determined the need of CCR-2
signaling in joint formation (E14.5) as well as its persistent effect
at a later stage (E18.5). As shown in Figure 3B, blockade of
MCP-5 signaling in Tgfbr2Prx1KO embryos in vivo was sufficient
to restoreGdf5 expression andCollagen 2 segmentation in E14.5
embryos. These effects were maintained in E18.5 Tgfbr2Prx1KO
embryos resulting in a well-defined joint space in between the
growth plates (Figure 3C). Blockade of MCP-5 signaling in NC
limbs, both ex vivo and in vivo, did not affect joint maturation
and chondrocyte segmentation (Figures 3A–3B). Our results
indicate that a downregulation of MCP-5 in developing interzone
is needed for proper joint formation, Gdf5 and Collagen 2 ex-
pressions, and reveal the critical role for TGF-b signaling in con-
trolling restrained levels of MCP-5 within the developing joints.
MCP-5 Acts as a Chondrogenic Factor on Isolated
Interzone Cells, and TGF-b Inhibits MCP-5 Expression
on Isolated TbRII+ Cells
We have recently reported that within the interphalangeal joints
TbRII-expressing cells localize in specific niches, such as the
Figure 3. Rescue of Tgfbr2Prx1KO Joint Phenotype by
Ex Vivo HGC-MC-21 Limb Implantation and RS-504393
In Vivo Treatment
(A) MC-21 antibody was loaded into HGC-nano-particle, and the
resulting HGC-MC-21 complex (MC-21, 1.5 ng) was implanted in
the interzone of dissected E14.5 NC and Tgfbr2Prx1KO digits.
Limbs were cultured for 48 hr, embedded in paraffin, and sub-
jected either to hematoxylin staining or ISH analyses using Gdf-5,
Col2, and Sox9 probes.
(B and C) RS-504393 treatments were started at E11.5 on preg-
nant females potentially carrying Tgfbr2Prx1KO embryos and
continued until either (B) E14.5 (3-day treatment) or (C) E18.5
(7-day treatment); embryos were then harvested and genotyped.
NC and Tgfbr2Prx1KO limbs were dissected, embedded in paraffin,
and subjected either to hematoxylin staining or ISH analyses
using Gdf-5 and Col2 probes (proximal side: left). All of the four
Tgfbr2Prx1KO embryos implanted with HGC-MC-21 showed the
phenotype described in the Results; for the RS-504393 treat-
ments, all of the four Tgfbr2Prx1KO embryos treated for 3 days and
all of the nine Tgfbr2Prx1KO embryos treated for 7 days showed
the phenotype described in the Results; analyses were performed
in at least three sections for each embryo and for each probe.
The evaluation of CCR2 expression by IHC at different joint
developmental time points (E12.5; E13.5, E14.5, and E18.5) is
shown in Figure S2.
Developmental Cell
TbRII/MCP-5 Axis in Limb Developmentventral and dorsal sites of the interzone (Figure S3) (Li et al.,
2011). Reasoning that TbRII-expressing cells control the devel-
oping environment of the interzone through paracrine and auto-
crine mechanisms, we relied on the microarray analysis as a
source to identify additional genes that encode for membrane-
associated proteins that are exclusively expressed in the
interzone of NC but not in Tgfbr2Prx1KO mice (i.e., Jagged1
and Pdgfrb) to isolate interzone cells from E14.5 autopod
mesenchyme. An immunomagnetic selection system was
used to isolate Jagged1-, TbRII-, and PDGFRb-positive (Jag+/
TbRII +/PDGFR+) cells that accounted for 1% of the total
(30 3 106 total cells from 30 embryos). mRNA was collected
immediately after cell separation from the Jag+/TbRII+/PDGFR+
cell fraction and subjected to RT-PCR. As shown in Figure 4A,
Jag+/TbRII+/PDGFR+ cells expressed key joint markers, such
as Gdf5, Wnt9a, Sulf1, and Collagen1. With the purpose of
understanding the effect of MCP-5 on interzone cells, we
cultured the isolated Jag+/TbRII+/PDGFR+ fraction in micromass
and treated them with or without MCP-5 (20 ng/ml) for 3 days.
MCP-5 induced a chondrogenic-like phenotype in the cells
that condensate in typical chondrogenic nodules (Figure 4B).
In addition, MCP-5 treatment determined a marked decrease
in the expressions of Gdf5, Wnt9a, and Sulf1, while increasing
Collagen 2, compared with untreated cells (Figure 4C). These
in vitro data support our ex vivo and in vivo findings, indicating
that a downregulation of MCP-5 is needed in interzone cells to
allow a correct expression of key joint markers. The chondro-
genic action of MCP-5 can be the consequence of severalDevelopmemechanisms ranging from proliferation to regula-
tion of transcription of chondrogenic gene markers.
Future investigations will be needed to dissect such
mechanisms.
Hypothesizing that only the TGF-b signaling regu-
lates MCP-5 expression, we exclusively isolatedTbRII-expressing cells (TbRII+) from E14.5 limb mesenchyme of
Tgfbr2-GFP-b-GEO-BAC transgenic mice. Tgfbr2-GFP-b-GEO-
BAC mice contain both GFP and LacZ as imaging reporters
for Tgfbr2 expression (Spagnoli et al., 2007). TbRII+ cells were
FACS sorted using GFP as isolation marker and cultured in
micromass for 18 hr with or without TGF-b (20 ng/ml). qRT-PCR
analyses showed that TGF-b significantly decreased Mcp5
expression compared to untreated controls (Figure 4D). These
results support our hypothesis that TGF-b is needed to downre-
gulate MCP-5 expression.
Aberrant Release ofMCP-5within theDeveloping Joints
of WT Mice Alters the Growth Plate Organization, while
Blockade of CCR2 Signaling in Tgfbr2Prx1KO Mutants
Restores the Growth Plate Phenotype
Because lack of joint development in Tgfbr2Prx1KO mice was
associated with selective perturbative effects on the adjacent
growth plate chondrogenesis with deregulated Ihh expression
and blockage of prehypertrophic to hypertrophic chondrocyte
progression (Spagnoli et al., 2007), we decided to investigate
the contribution of MCP-5 to such derangements. ISH studies
of ex vivo limb cultures injected with HGC-MCP-5 showed
that the aberrant release of MCP-5 within the interzone of
WT mice impaired Ihh spatial organization, producing a diffuse
pattern of expression along the growth plate, and significantly
decreased Collagen10 expression by hypertrophic chondro-
cytes (Figure 5). These results indicate that the aberrant pres-
ence of MCP-5 within the joint leads to a signal from the jointsntal Cell 23, 71–81, July 17, 2012 ª2012 Elsevier Inc. 75
Figure 4. MCP-5 Effect on Joint Interzone Cells and Rele-
vance of TbRII Signaling in Regulating Its Expression
In Vitro
(A–C) Jag+/TbRII+/PDGFR+ cells were isolated from E14.5 WT
autopods. (A) mRNA was collected after cell separation and
subjected to RT-PCR for Collagen1 (Col1), Gdf5, Wnt9a, and
Sulf1. (B and C) Micromass cultures of isolated Jag+/TbRII+/
PDGFR+ were treated ± MCP-5 (20ng/ml) for 3 days and analyzed
for morphology (B) and gene expression by RT-PCR for Gdf5,
Wnt9a, Sulf1, and Col2 (C).
(D) TbRII+ cells were FACS sorted from limb buds cells isolated
from Tgfbr2-GFP-b-GEO-BAC digits using GFP as selection
marker for TbRII expression. Micromass cultures of TbRII+ cells
were treated ± TGF-b (20 ng/ml) for 18 hr and analyzed for MCP-5
expression by qRT-PCR (n = 3; mean ± SD; *p = 0.0425 by one-
tailed Student’s t test). For RT-PCR experiments, gel lanes
correspond to different experiments that were repeated at least
three times with similar results. The localization of TbRII-ex-
pressing cells within the interphalangeal joints is visualized in
Figure S3.
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maturation. It is important to remark that ex vivo cultured limbs
progress to chondrocyte maturation. As depicted in Figure S4,
histological and ISH analyses showed that E14.5 limbs cultured
ex vivo for 2 days progress toward chondrocyte hypertrophy, as
indicated by the increase in Collagen10 expression when
compared to E14.5 uncultured limbs.
To analyze whether the elevated MCP-5 levels found in
Tgfbr2Prx1KO mutants contributed to the failure of hypertrophic
chondrocyte maturation, we analyzed if blockade of MCP-5
signaling in the presumptive interzone of Tgfbr2Prx1KO by both
ex vivo and in vivo approaches, rescued the growth plate pheno-
type. Histological and ISH studies demonstrated that both
ex vivo HGC-MC21 implant and in vivo RS-504383 treatment
in Tgfbr2Prx1KO embryos rescued the Ihh spatial organization
and restored Collagen10 and Collagen1 expressions to levelsFigure 5. Aberrant Expression of Ihh and Collagen10 in E14.5 WT
Embryos after Ex Vivo HGC-MCP-5 Limb Implantation
Recombinant MCP-5 was loaded in HGC-nano-particle, and the resulting
HGC-MCP-5 complex (MCP-5, 1.5 ng) was implanted in the interzone of
dissected E14.5 WT digits. Limbs were cultured for 48 hr, embedded in
paraffin, and subjected to ISH analyses using Ihh and Collagen10 (Col 10)
probes (proximal side: left). Eight out of nine WT embryos implanted with
HGC-MCP-5 showed the altered phenotype; analyses were performed in at
least three sections for each embryo and for each probe. Figure S4 shows
that in limb explants, growth plate chondrocytes are capable to progress to
hypertrophy after 2-day ex vivo culture.
76 Developmental Cell 23, 71–81, July 17, 2012 ª2012 Elsevier Inc.similar to the NC (Figures 6A–6B). Notably, in ex vivo, as well
as in vivo, studies, blockade of MCP-5 signaling in NC deter-
mined an increase in Collagen10 and Collagen1 expressions
and a reduction in size of the primary ossification center that
appeared to undergo to rapid mineralization (Figures 6A–6B).
These findings point out that MCP-5 plays an additional role in
the growth plate maturation, which in this case is independent
from the TbRII signaling.
DISCUSSION
Our results demonstrate that within the joint interzone a down-
regulation of MCP-5 is critical to drive proper joint and endo-
chondral development and that TbRII signaling is needed in
maintaining such downregulation. Furthermore, we determined
that the TbRII-independent expression of MCP-5 within the
growth plate plays a role in chondrocyte maturation and hyper-
trophy. Taken together, these results lead us to propose the
model shown in Figure 7. In this model we propose that a cross-
talk between the forming interzone and the developing growth
plate, mediated by MCP-5 through TbRII-dependent and
TbRII-independent mechanisms, is critical for proper joint and
skeletal development. Our findings represent a paradigm shift
in the joint biology research field that presently perceives joints
as the passive victims of inflammatory cytokines that cause their
degeneration. Instead, our studies demonstrate that joints hold
an active developmental mechanism that is operated by the
TbRII signaling to tightly regulate the expression of cytokines,
such as MCP-5, and that such mechanism is essential for joint
morphogenesis.
TbRII/MCP-5 Axis in Joint Development
Though no one disputes that interzone is needed for joint forma-
tion, there is limited information on the interzone joint-forming
cell population, and the role that these cells play in the process
remains far from clear. The formation of the interzone is specified
by an inductive signal in a restricted area of the chondrogenic
Figure 6. Blockade of CCR-2 Signaling, Both Ex Vivo and
In Vivo, Rescues the Tgfbr2Prx1KOGrowth Plate Phenotype
and Advances Ossification in NC Growth Plates
(A) MC-21 antibody was loaded in HGC-nano-particle and the
HGC-MC-21 complex (MC-21, 1.5 ng) was implanted in the
interzone of dissected E14.5 NC and Tgfbr2Prx1KO digits. Limbs
were cultured for 48 hr, embedded in paraffin, and subjected to
hematoxylin staining and ISH analyses using Ihh, Col10, and
Collagen1 (Col1) probes.
(B) RS-504393 treatments were started at E11.5 on pregnant
females potentially carrying Tgfbr2Prx1KO embryos until E18.5
(7-day treatment), when embryos were harvested and genotyped.
NC and Tgfbr2Prx1KO limbs were dissected, embedded in paraffin,
and subjected either to hematoxylin staining or ISH analyses
using Ihh, Col10, and Col1 probes (proximal side, left). All of the
four Tgfbr2Prx1KO embryos implanted with HGC-MC-21 and all
the nine Tgfbr2Prx1KO embryos treated with RS-504393 showed
the phenotype described in the Results; analyses were performed
in at least three sections for each embryo and for each probe. The
evaluation of CCR2 expression by IHC at different joint develop-
mental time points (E12.5; E13.5, E14.5, and E18.5) is shown in
Figure S2.
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while joint marker (i.e., GDF-5)-expressing cells emerge and
segment the adjacent growth plates. It is unclear whether
Collagen 2-expressing cells undergo a selection process (cell
death) or whether their transcriptome becomes programmed
only toward joint marker expression (Khan et al., 2007). Com-
bining LCM with gene-profiling analyses, we found that the
progenitor joint-forming interzone cells develop in a setting
that is distinct from the setting of the adjacent growth plate
chondrocytes and characterized by a downregulation of specific
cytokines/chemokines, such as MCP-5. Our ex vivo studies
demonstrate that this differentially controlled expression of
MCP-5 in the interzone versus the adjacent chondrocytes is
essential for the proper process of interzone formation leading
to expression of key joint markers (such as Gdf5), as well as
the correct segmentation of adjacent growth plates. Consis-
tently, the aberrant release of MCP-5 within the interzone inter-
fered with its initiation and halted the segmentation process.
Furthermore, in our in vitro experiments we demonstrated a
direct effect of MCP-5 on isolated interzone cells, characterized
by a marked decrease in the expression of key joint markers
(Gdf5, Wnt9a, and Sulf1) and accompanied by a stimulation of
Collagen 2 expression and emergence of a chondrogenic
phenotype. Our data support the hypothesis that interzone
cells are capable of being committed to either joint-forming cells
or chondrocytes and that MCP-5 plays a critical role in directing
their differentiative program.DevelopmeWe have previously reported that the joints of
Tgfbr2Prx1KO mutants appear to be arrested in their
development about the time when interzone starts to
develop; differentiated chondrocytes extend with a
continuous pattern across the phalanges, lacking
interzone cell condensation and Jagged-1, Noggin,
and Gdf-5 expressions (Spagnoli et al., 2007). In the
present study, we found that MCP-5 downregula-
tion was completely impaired in the interzone of
Tgfbr2Prx1KO mice, indicating that TbRII signaling isneeded to control MCP-5 expression and suggesting that the
failure of the mutant’s joint formation may be due to the aberrant
expression of MCP-5. Our ex vivo and in vivo studies sustained
this hypothesis showing that in Tgfbr2Prx1KO mice, the inhibition
of MCP-5 activity by blocking its receptor, CCR2, restored
joint formation and in particular Gdf-5 expression and chondro-
cyte segmentation. Furthermore, a direct inhibitory action of
TGF-b on MCP-5 expression was found in our in vitro studies
by treating TbRII+ cells (isolated from limb bud mesenchyme)
with TGF-b. These findings classify MCP-5 as a key downstream
mediator of TbRII signaling in its critical role as a joint-forming
initiator. We postulate that interzone cells are programmed
by the TbRII signaling to commit to joint-forming cells by repres-
sing MCP-5/CCR2 signaling, while halting their differentiative
program to Collagen 2-expressing chondrocytes.
MCP-5, its human homolog MCP-1, and its receptor CCR-2
have been largely studied in the arthritic process. The current
hypothesis is that those MCPs are produced and act primarily
through inflammatory cells (mostly monocytes) that are recruited
within the arthritic joints (Haringman and Tak, 2004; Tak, 2006).
Although there are substantial pharmacological data supporting
a role for CCR2 antagonists in improving the course of experi-
mental arthritis, reports with CCR2 knockout and anti-CCR2
blocking antibody (MC-21) have provided contrasting results.
In fact, CCR2 knockout mice are more susceptible to develop
arthritis, and in experimental arthritis MC-21 treatment improved
the disease when given at an early stage while worsened whenntal Cell 23, 71–81, July 17, 2012 ª2012 Elsevier Inc. 77
Figure 7. A Model for the TbRII+/MCP-5 Axis during Joint and
Growth Plate Development
(A) Wild-type, WT, mice: TbRII downregulates MCP-5 expression in the
interzone, allowing expression of key joint markers (such as Gdf5) while in-
hibiting Collagen 2 expression. In the growth plate, the downregulation of
interzoneMCP-5 (TbRII-dependent) signals the correct Ihh expression pattern,
promoting chondrocyte maturation, while MCP-5 within the growth plate
(TbRII-independent) inhibits chondrocyte terminal differentiation. The balance
between these two opposite signals is necessary for a proper endochondral
ossification process.
(B) Tgfbr2Prx1KO mutants: Lack of the TbRII signaling leads to upregulation of
interzoneMCP-5 with consequent lack of joint formation. Furthermore, MCP-5
abnormal upregulation in the interzone does not counteract the MCP-5
inhibitory action coming fromwithin the growth plate and enhances Ihh altered
distribution with consequent impairment in chondrocyte hypertrophy and
ossification.
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TbRII/MCP-5 Axis in Limb Developmentgiven later (Bru¨hl et al., 2004). Clinical studies using different
interventions to block the MCP5/CCR-2 axis in patients with
RA have showed disappointing results (Quinones et al., 2005).
CCR2 is expressed in chondrocytes, but its function is unknown
(Borzı` et al., 2000; Pulsatelli et al., 1999). Our data provide
evidence for a role of the MCP-5/CCR-2 system that targets
directly the joint cells. Future studies will be important to
determine whether the TbRII signaling regulates MCP-5 ex-
pression to maintain articular cartilage integrity in adulthood.
In this respect, the OA/RA process could be seen as the failure
of an active cell joint population (TbRII cells) that is preserved
throughout life to maintain a controlled cytokine environment78 Developmental Cell 23, 71–81, July 17, 2012 ª2012 Elsevier Inc.rather than the result of passive joint cell degeneration due to
the influx of inflammatory cells. The lack of CCR2 in the knockout
mice and the timing of the blockage by theMC-21 antibody in the
OA studies may have perturbed the TbRII/MCP-5 equilibrium
either in the wrong cells or at the wrong time. Consistent with
this hypothesis is our observation that TbRII-expressing cells
localize in specific niches (Li et al., 2011).
TbRII/MCP-5 in Endochondral Cartilage Development
It has been hypothesized that the developing joint acts as
signaling center to control the adjacent endochondral template
development (Archer et al., 2003). Our ex vivo studies showed
that release of MCP-5 within the interzone leads to an impair-
ment of Ihh spatial organization and to a decrease of Collagen10
expression. Notably, this phenotype coincided with the one
observed in the Tgfbr2Prx1KO mutants, suggesting a role for
MCP-5 in the failure of the mutant’s chondrocyte progression
to hypertrophy. This hypothesis was corroborated by our
ex vivo and in vivo experiments: blockade of MCP-5 signaling
in Tgfbr2Prx1KO mice rescued Ihh, Collagen10, and Collagen1
expression patterns. Taken together, these results clearly indi-
cate the need for TbRII signaling in maintaining low levels of
MCP-5 in the interzone and therefore to signal, through a still
undefined factor, the adjacent growth plate templatematuration.
Future studies are needed to identify such factor(s); potential
candidates could be members of WNT family. The interzone
expresses several members of the Wnt/b-catenin system that
seem to be involved in joint formation (Hartmann et al., 2000;
Hartmann and Tabin, 2001; Luyten et al., 2009; Spa¨ter et al.,
2006). In addition, Wnt9a and b-catenin regulate Ihh expression
(Spa¨ter et al., 2006). Because, in isolated interzone cells, we
found an inhibitory effect of MCP-5 on Wnt9a expression and
demonstrated a TbRII-dependent role for MCP-5 in regulating
Ihh spatial organization in vivo, we speculate Wnt9a as the
missing ring linking MCP-5 and Ihh expressions and foresee
future studies in this direction.
An outstanding question is what role, if any, does MCP-5
expressed by chondrocytes within the growth plate play in the
endochondral mineralization process? Our data contribute to
answer this question. We found that in normal limbs, the inhibi-
tion of MCP-5 activity within the growth plate resulted in an in-
crease ofCollagen10 by hypertrophic chondrocytes and, at later
stages, Collagen1 in the ossification center. These findings indi-
cate that, in addition to its indirect action from the joints, MCP-5
within the growth plate affects the growth plate maturation, in-
hibiting hypertrophy. Because the lack of TbRII signaling in the
Tgfbr2Prx1KOmutants does not seem to affect MCP-5 expression
in the growth plate, it is likely that this effect ofMCP-5 is indepen-
dent of TbRII signaling. Interestingly, blockade of MCP-5 activity
in Tgfbr2Prx1KOmutants, did not lead to an increase inmineraliza-
tion. One explanation could be that in normal mice, differently
from Tgfbr2Prx1KO mutants, blockade of the MCP-5-dependent
inhibitory action on chondrocyte maturation could be additive
with the MCP-5-TbRII-dependent mechanism(s) promoting
hypertrophy and ossification. Because MCP-5 is undetectable
in normal interzone, no changeswere noted during joint develop-
ment of control mice as a consequence of MCP-5 inhibition.
These findings indicate that the presence of MCP-5 in the
growth plate has no effect on joint development.
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Plate Development
In Figure 7, we propose a dual role for MCP-5: it regulates cell
commitment to either joint-forming cells or chondrocytes within
the joints and blocks the progression to chondrocyte hyper-
trophy and mineralization within the growth plate. These
MCP-5 actions are TbRII-dependent within the joints while
TbRII-independent in the growth plate (Figure 7A). Specifically,
TbRII signaling, by blocking MCP-5 expression in the interzone,
halts Collagen 2 expression, induces interzone specific markers
(i.e., Gdf5), and signals to the growth plate in favor of chondro-
cyte hypertrophy by proper Ihh expression. On the other end,
MCP-5 within the growth plate, through a TbRII-independent
mechanism, inhibits chondrocyte hypertrophy. The balance
between these two opposite signals, by tightly regulating
the number of chondrocytes proceeding toward terminal differ-
entiation, is necessary for a proper endochondral ossification
process.
The model in Figure 7B shows the TbRII contribution to
the MCP-5 actions: in Tgfbr2Prx1KO mutants, lack of the TbRII
signaling leads to disregulated levels of interzone MCP-5 that,
in turn, block expression of interzone-specific markers (i.e.,
Gdf5), while increasing Collagen 2-expressing cells, with conse-
quent accumulation of chondrocytes within the joint region. In
addition, MCP-5 upregulation in interzone is accountable for
the impairment in Ihh spatial organization that alters the number
of chondrocytes undergoing hypertrophy and does not coun-
teract theMCP-5-inhibitory effect coming fromwithin the growth
plate. As consequence, there is an accumulation of disorganized
prehypertrophic chondrocytes throughout the growth plate.
Blockade of MCP-5 in Tgfbr2Prx1KO mutants is sufficient to
rescue both their joint phenotype and chondrocyte maturation,
indicating in MCP-5 a key regulator for the TGF-b action.EXPERIMENTAL PROCEDURES
Mouse Strains
Tgfbr2Prx1KO mutants were generated as previously reported by crossing
Tgfbr2flox/flox homozygous females, defined as Normal Control (NC) in the
manuscript, with males Prx-1-Cre (provided by C. Tabin, Harvard University)
(Spagnoli et al., 2007). In the Prx-1-Cre mouse, the Prx-1 limb enhancer drives
Cre recombinase expression in limb buds beginning at E9.5 (Logan et al.,
2002). Experiments were performed in mice that were C57BL/6 strain for at
least ten generations. Tgfbr2-GFP-b-GEO-BAC mice were generated as
previously reported (Spagnoli et al., 2007).
For all timed pregnancies, noon of the day when evidence of a vaginal plug
was found was considered E0.5. All animal procedures were approved by
the animal care committees of Vanderbilt University and University of North
Carolina at Chapel Hill.
LCM for RNA Sampling and Microarray Analysis
We obtained E14.5 autopods from two NC and two Tgfbr2Prx1KO littermate
embryos. Samples were frozen in OTC and cryosectioned (6 mm), then pro-
cessed with ethanol and xylene, and subjected to LCM. To minimize RNA
degradation, the process from sectioning to shipment was performed in less
than 20 min. We sequentially laser-captured cells in the interzone and the
adjacent growth plates from NC and Tgfbr2Prx1KO mutants (n = 2). In the
Tgfbr2Prx1KO sections the presumptive interzone was identified as a bending
between two growth plates (Figure 1A arrow). Captured specimens were
frozen in SuperAmp Lysis Buffer (Miltenyi Biotec, Cologne, Germany) and
shipped to Miltenyi Biotec. mRNA was extracted and transcribed into cDNA
in accordance with Miltenyi Biotec’s undisclosed procedure (SuperAmpDMiltenyi Biotec). The average length of cDNA products, measured and
analyzed via the Agilent 2100 Bioanalyzer platform and software (Agilent
Technologies), ranged from 200–1,000 bp, indicating the integrity of the
cDNAs. The purified PCR products (250 ng) were labeled with Cy3-dCTP
and hybridized to an Agilent Whole Mouse Genome Oligo Microarrays
4X44K for 17 hr at 65C in accordance with Miltenyi Biotec’s undisclosed
protocol. Washing, staining, and scanning of the microarrays were performed
using the Agilent Technologies equipment. Signal intensities from the single-
experiment data were normalized by dividing the intensity values by their
median. Normalized data were expressed as fold changes of a candidate
gene in the interphalangeal interzone sample compared to that obtained in
chondrocytes using the Resolver (Rosetta Biosoftware). Pathway analysis
was performed using the PANTHER Classification System (Celera) (Thomas
et al., 2003). Lists of putative candidate genes with a fold change ± 2 and
p value 0.01 were compared to a reference list (Mus musculus, NCBI) using
a binomial test.
Preparation of HGC-MCP-5/MC21 Nanoparticles, Implantation,
and Ex Vivo Limb Cultures
HGC nanoparticles were prepared as previously reported (Li et al., 2010).
Briefly, 25 mg of either recombinant mouse MCP-5 (R&D Systems, Minneapo-
lis, MN, USA) or MC-21 antibody (anti-CCR2) (donated by M. Mack, Regens-
burg University) (Mack et al., 2001) were encapsulated into 250 mg of HGC
nanoparticles. Methylene blue was added to the mixture to mark the injection
site. HGC-protein implantation was performed using a microinjection unit
(Picosprizer II) that allowed for precise localization of the injection and volume
accuracy (0.0015 ml/shot) as previously described (Li et al., 2010). HCG-protein
implants (joint site) were performed in WT, NC, or Tgfbr2Prx1KO by delivering
either HGC-MC-21 (1.5 ng, 5-shots, 0.3 ng/shot) or increasing doses of
HGC-MCP-5 (0.9, 1.5, 3, and 6 ng). Limbs were cultured in BGJb medium
for 48 hr. HGC-protein implantation was performed within the medial interpha-
langeal joint of 2nd, 3rd, and 4th digit and the 5th uninjected digit of the same
limb was used as controls. The forming or presumptive interphalangeal joint
was identified as the bending between two adjacent growth plates.
RS-504393 In Vivo Treatment
Pregnant NC females potentially generating Tgfbr2Prx1KO mice, were treated
with 4 mg/Kg/day of RS-504393 (Tocris Bioscience, Minneapolis, MN, USA),
orally (in drinking water), starting at 11.5 days of gestation, for a total of either
3 (E14.5) or 7 days (E18.5). After euthanasia of the mother, limbs from either
E14.5 or E18.5 embryos were dissected and prepared for histological studies.
Genotyping was used to confirm the mutant phenotype; RS-504393-treated
NC littermates and NC untreated mice were used as controls.
Isolation and Culture of Jag+/TbRII+/PDGFR+ Cells and TbRII+ Cells
To obtain mesenchyme limb bud cells, the distal tips of E14.5 autopods from
either WT or Tgfbr2-GFP-b-GEO-BAC embryos were dissected and digested
with dispase (1 U/ml), as previously reported (Spagnoli et al., 2007). To obtain
Jag+/TbRII+/PDGFR+ cells, WT mesenchyme limb bud cells were subjected to
immunoselection using biotinylated TbRII, biotinylated PDGFRB (BAF532 and
BAF1042; R&D Systems) and Jagged 1 (sc-6011; Santa Cruz Biothechnolgy,
Santa Cruz, CA, USA) antibodies. Biotinylation of Jagged1 antibody was
performed using Lightning-Link Biotin Conjugation Kit (Innova Biosciences,
Cambridge, UK) following the manufacturer’s protocol. Immunoselection
was performed in a MACS magnetic system (Miltenyi) as previously described
(Longobardi et al., 2006). Isolation of TbRII+ cells was performed by FACS sort-
ing (MoFlo, Beckman Coulter, Fullerton, CA, USA) mesenchyme limb bud cells
from Tgfbr2-GFP-b-GEO-BAC that contain GFP as gene reporters for Tgfbr2
(Spagnoli et al., 2007). Micromass cultures were performed as previously re-
ported (Spagnoli et al., 2007). Jag+/TbRII+/PDGFR+ or TbRII+ cells were
treated with ± 20ng/ml MCP-5 (for 3 days) or with ± 20 ng/ml TGF-b (for
18 hr), respectively.
Histology, IHC, and ISH
Dissected limbs from E14.5 to E18.5 embryos were fixed overnight in 4% PFA
at 4C, paraffin embedded, and sectioned at 5 mm thickness. Hematoxylin
staining was performed following standard protocols.evelopmental Cell 23, 71–81, July 17, 2012 ª2012 Elsevier Inc. 79
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TbRII/MCP-5 Axis in Limb DevelopmentFor IHC, the Vectastain Elite ABC Kit (DakoCytomation) was used. The
following primary antibodies were used: anti-MCP-5 (G12) polyclonal (sc-
33226, SantaCruz) and anti-CCR-2monoclonal (ab32144, Abcam,Cambridge,
UK). Histological sections were counterstained with hematoxylin.
ISH studies were performed as previously reported using DIG-labeled
probes (Spagnoli et al., 2007). The MCP-5 plasmid used to generate the
MCP-5 probe was provided by Dr. Karin E. Peterson (Louisiana State Univer-
sity). After hybridization, probes were detected by incubation with anti-DIG-AP
antibody (Roche, Mannheim, Germany, dilution 1:5,000).
Images were formatted without using any imaging enhancement.
Quantitative Real-Time PCR
mRNA from experiments using Jag+/TbRII+/PDGFR+ cells and TbRII+ cells was
extracted and reversed transcribed into cDNA by using mMACS mRNA Isola-
tion and cDNA Synthesis kit (Miltenyi Biotec). cDNAs (including from LCM)
were analyzed by qRT-PCR (MyIQ) using SYBR Green followed by Gene
Expression Analysis Software (Bio-Rad, Hercules, CA, USA). Expression of
genes of interest were normalized using either GAPDH or b-actin expressions.
Statistics
Data are presented as mean ± SD. Statistical differences between groups
were assessed by one-way ANOVA followed by Bonferroni’s Multiple Com-
parison test for all pairwise multiple comparisons or unpaired Student’s
t test (GraphPad Prism Software, San Diego, CA, USA).
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